[Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
D000970:Antineoplastic Agents / Q000627:therapeutic use; D003606:Dacarbazine / Q000009:adverse effects / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D009362:Neoplasm Metastasis; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; D003606:Dacarbazine; C054368:fotemustine
La fotémustine dans l'indication "mélanome malin métastatique". Analyse globale des résultats.